Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial
- Koole, S.N.
- van Lieshout, C.
- van Driel, W.J.
- van Schagen, E.
- Sikorska, K.
- Kieffer, J.M.
- Schagen van Leeuwen, J.H.
- Schreuder, H.W.R.
- Hermans, R.H.
- de Hingh, I.H.
- van der Velden, J.
- Arts, H.J.
- Massuger, L.F.A.G.
- Aalbers, A.G.
- Verwaal, V.J.
- Van de Vijver, K.K.
- Aaronson, N.K.
- van Tinteren, H.
- Sonke, G.S.
- van Harten, W.H.
- Retèl, V.P.
DOIAbstract
PURPOSE: In the randomized open-label phase III OVHIPEC trial, the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery (CRS) improved recurrence-free and overall survival in patients with stage III ovarian cancer. We studied the cost effectiveness of the addition of HIPEC to interval CRS in patients with ovarian cancer. PATIENTS AND METHODS: We constructed a Markov health-state transition model to measure costs and clinical outcomes. Transition probabilities were derived from the OVHIPEC trial by fitting survival distributions. Incremental cost-effectiveness ratio (ICER), expressed as euros per quality-adjusted life-year (QALY), was calculated from a Dutch societal perspective, with a time horizon...
Add to ORKG